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Quality by Design (QbD) has been widely adopted by the pharmaceutical industry as a tool for transforming
development, manufacture, and commercialization of drug products. QbD ensures that quality is built into a
manufacturing process to consistently produce desired product. As per a FDA guidance1, QbD should be
employed at the product development stage to ensure manufacture of a product with predefined quality. Here
we present a retrospective QbD approach employed at Shire to define an improved control strategy for a
commercial process using risk-based process understanding and characterization. Key challenges and
considerations of implementing a QbD strategy on a commercial process are presented with examples of critical
quality attribute review, parameter impact assessment, parameter classification review and updated control
strategy.
1US

Food and Drug Administration. Guidance for industry: Q10 quality systems approach to pharmaceutical
cGMP regulations (FDA, Rockville, MD, September 2006).

